Ownership and insider activity for Century Therapeutics, Inc. (IPSC): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments.
Price
| Price | $1.86 |
| Market Cap | $161M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-14 | Russotti Gregory | S-Sale | 2,587 | $5K |
| 2026-09-14 | Carr Douglas | S-Sale | 1,658 | $3K |
| 2026-09-11 | Pfeiffenberger Brent | F-InKind | 13,850 | $27K |
| 2026-09-09 | Truitt Joseph | A-Award | 148,000 | $300K |
| 2026-09-09 | Truitt Joseph | |||
| 2026-09-04 | Pfeiffenberger Brent | F-InKind | 463 | $977 |
| 2026-09-08 | Russotti Gregory | S-Sale | 534 | $1K |
| 2026-09-08 | Carr Douglas | S-Sale | 254 | $521 |
| 2026-08-14 | Pfeiffenberger Brent | F-InKind | 31,172 | $60K |
| 2026-08-03 | Carr Douglas | S-Sale | 275 | $544 |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $44.1M | $27.2M | $56.4M | $84.3M | $47.3M | $58.4M | $61.9M |
| Short-term Investments | $37.5M | $48.5M | $166.4M | $231.2M | $125.4M | $130.9M | $55.3M |
| Receivables | $123000 | $908000 | $250000 | $780000 | $665000 | $1.5M | $667000 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $84.1M | $78.8M | $228.2M | $319.7M | $177.0M | $194.1M | $120.8M |
| Property, Plant & Equipment | $2.5M | $24.8M | $69.8M | $111.7M | $92.1M | $90.8M | $66.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | $9.4M | 0 | 0 | 0 | $34.2M | $34.2M |
| Total Assets | $90.9M | $106.8M | $437.4M | $486.5M | $360.7M | $353.2M | $223.7M |
| Accounts Payable | $1.5M | $8.1M | $7.6M | $5.5M | $2.7M | $3.1M | $4.8M |
| Short-term Debt | 0 | 0 | $1.0M | $6.5M | $1.5M | 0 | 0 |
| Total Current Liabilities | $3.0M | $12.1M | $15.7M | $29.8M | $17.8M | $129.8M | $20.2M |
| Long-term Debt | 0 | $9.6M | $8.9M | $3.7M | 0 | 0 | 0 |
| Total Liabilities | $182.8M | $213.2M | $41.1M | $183.8M | $175.9M | $191.9M | $64.8M |
| Retained Earnings | -$238.8M | -$292.3M | -$388.2M | -$519.1M | -$655.8M | -$782.3M | -$791.9M |
| Total Equity | -$91.9M | -$106.4M | $396.2M | $302.7M | $184.8M | $161.4M | $158.9M |
| Total Debt | 0 | $21.6M | $25.1M | $49.4M | $48.2M | $53.8M | $43.6M |
| Net Debt | -$81.5M | -$54.2M | -$197.8M | -$266.1M | -$124.6M | -$135.5M | -$73.5M |
| Working Capital | $81.1M | $66.7M | $212.5M | $289.9M | $159.1M | $64.3M | $100.5M |
Financial Health
| Debt / Equity | 0.15 |
| Current Ratio | 8.28 |
Profitability
| Return on Equity | -52.76% |
| Return on Invested Capital | -43.66% |
| Return on Assets | -38.25% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: COEP · CUE · EQ · GNTA · KPTI · MDCX · OSTX
Explore sector: Healthcare · Biotechnology
More sections of IPSC: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks